Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAmgen CDR (CAD Hedged)

Amgen CDR (CAD Hedged)

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
35.38 CAD 1.29 ( 3.78%)
Last update at 2026-11-04T20:30:00Z
VOLUME
12611
Market Cap
188792.80M
P/E
24.19

Momentum Score

…

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
34.45
Low
35.46
High
52 Week Price Range
20.29
Low
29.21
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Amgen CDR (CAD Hedged) gives Canadian investors exposure to Amgen, a large biopharmaceutical company with approved biologics and a late-stage R&D pipeline in oncology and inflammatory disease. Long-term growth may be supported by product launches, pipeline approvals and the CAD-hedge that reduces U.S. dollar exposure for Canadian holders. The company appears positioned to produce stable cash flows and return capital to shareholders.
Investment risks include patent expiries and biosimilar competition, pricing and reimbursement pressure, and clinical or regulatory setbacks that could materially affect revenues.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
34.09
Dividend Yield
36.43%
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
10610.25%
Net Debt
-
ROCE
13.95%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax 8976.00M 4609.00M 7855.00M 7346.00M
Net income 7711.00M 4090.00M 6717.00M 6552.00M
Selling general administrative 6942.00M 7096.00M 6166.00M 5414.00M
Gross profit 30328.00M 22966.00M 19775.00M 19917.00M
Operating income 9080.00M 7473.00M 8122.00M 9644.00M
Tax provision 1265.00M 519.00M 1138.00M 794.00M
Interest income -732.00M 3301.00M 2637.00M 1406.00M
Total revenue 36751.00M 33424.00M 28190.00M 26323.00M
Total operating expenses 27671.00M 25951.00M 20068.00M 16679.00M
Cost of revenue 6423.00M 10458.00M 8415.00M 6406.00M
Net income applicable to common shares 7711.00M 4090.00M 6717.00M 6552.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 90586.00M 91839.00M 97154.00M 65121.00M
Intangible assets 22276.00M 27699.00M 32641.00M 16080.00M
Other current assets 4133.00M 419.00M 281.00M 355.00M
Total liab 81928.00M 85962.00M 90922.00M 61460.00M
Total stockholder equity 8658.00M 5877.00M 6232.00M 3661.00M
Common stock - 33533.00M 33070.00M 32514.00M
Retained earnings - -27590.00M -26549.00M -28622.00M
Good will 18680.00M 18637.00M 18629.00M 15529.00M
Other assets 12660.00M 9111.00M 8709.00M 5071.00M
Cash and equivalents 9129.00M 11973.00M 10944.00M 7629.00M
Total current liabilities 25489.00M 23099.00M 18392.00M 15687.00M
Short term debt - 0.00M 0.00M 0.00M
Other stockholder equity 8658.00M -66.00M -289.00M -231.00M
Property plant equipment 7913.00M 7100.00M 6592.00M 6006.00M
Total current assets 29057.00M 29030.00M 30332.00M 22186.00M
Short term investments - - 0.00M 1676.00M
Net receivables 9570.00M 6782.00M 7268.00M 5563.00M
Long term debt 50005.00M 56549.00M 63170.00M 37354.00M
Inventory 6225.00M 6998.00M 9518.00M 4930.00M
Long term debt total 50005.00M 56549.00M 63170.00M 37354.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments 0.00M - - -
Total cashflows from investing activities -1943.00M -1046.00M -26204.00M -6044.00M
Net borrowings -5000.00M - - -
Total cash from financing activities -10859.00M -9415.00M 21048.00M -4037.00M
Net income 7711.00M 4090.00M 6717.00M 6552.00M
Change in cash -2844.00M 1029.00M 3315.00M -360.00M
Begin period cash flow 11973.00M - - -
End period cash flow 9129.00M - - -
Total cash from operating activities 9958.00M 11490.00M 8471.00M 9721.00M
Depreciation 5167.00M 5592.00M 4071.00M 3417.00M
Other cashflows from investing activities -85.00M 50.00M -25092.00M -5108.00M
Dividends paid 5124.00M 4832.00M 4556.00M 4196.00M
Change to inventory 886.00M - - -
Change to account receivables -2676.00M - - -
Sale purchase of stock 0.00M -200.00M 0.00M -6360.00M
Other cashflows from financing activities -52.00M -124.00M -72.00M -103.00M
Capital expenditures 1858.00M 1096.00M 1112.00M 936.00M
Change in working capital -1978.00M 2365.00M -484.00M -733.00M
Stock based compensation 494.00M - - -
Other non cash items 149.00M - - -
Free cash flow 8100.00M - - -

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AMGN
Amgen CDR (CAD Hedged)		 1.29
3.78%		 35.38 24.19 15.65 5.06 21.36 6.30 13.69
NOVO
Novo Nordisk CDR (CAD Hedged)		 0.92
5.27%		 18.37 3.31 3.54 1.10 1.74 3.88 7.66
MRK
Merck CDR (CAD Hedged)		 1.22
3.80%		 33.30 15.70 22.32 4.40 5.36 4.81 11.07
GILD
Gilead Sciences CDR (CAD Hedged)		 1.30
3.84%		 35.12 19.51 15.04 5.62 7.21 6.14 13.31
SNY
Sanofi CDR (CAD Hedged)		 0.60
2.84%		 21.74 3.25 1.53 0.34 0.22 2.33 8.73

Profile*

Amgen CDR (CAD Hedged)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

805 447 1000

https://www.amgen.com

28000

Name Title Year Born
Mr. Robert A. Bradway Chairman, CEO & President 1963
Mr. Peter H. Griffith Executive VP & CFO 1959
Dr. David M. Reese M.D. Executive VP & CTO 1963
Mr. Murdo Gordon Executive Vice President of Global Commercial Operations 1967
Dr. James E. Bradner M.D. Executive Vice President of Research & Development 1972
Mr. Esteban Santos Executive Vice President of Operations 1968
Mr. Matthew C. Busch Chief Accounting Officer & VP of Finance 1975
Mr. Scott Skellenger Senior VP & Chief Information Officer NA
Mr. Howard Y. Chang M.D., Ph.D. Senior VP of Global Research & Chief Scientific Officer NA
Casey Capparelli Executive Director of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…